Companies › Palvella Therapeutics
2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 2; Other; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sirolimus (PTX-022) FK506-binding protein 1A inhibitor | FKBP1A | Phase 3 | Pachyonychia Congenita; Cutaneous Venous Malformations; Angiokeratomas | Aug 2027 |
| QTORIN 3.9% Rapamycin Anhydrous Gel mTOR inhibitor | MTOR | Phase 3 | Microcystic Lymphatic Malformation | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05643872 | Sirolimus (PTX-022) | Phase 3 | Pachyonychia Congenita | Other | Oct 2023 |
| NCT06653842 | Sirolimus (PTX-022) | Phase 2 | Cutaneous Venous Malformations | Other | Nov 2025 |
| NCT06239480 | QTORIN 3.9% Rapamycin Anhydrous Gel | Phase 3 | Microcystic Lymphatic Malformation | Other | Jan 2026 |
| NCT07552077 | Sirolimus (PTX-022) | Phase 2 | Angiokeratomas | Other | Aug 2027 |
Cash and short-term investments of $237m on 2026-09-30; operating cash outflow about $51m a year; runway about 56 months at that burn, to May 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Restorbio Eisai CSPC ZhongQi Pharmaceutical Technology Novartis Rapamycin Holdings AgelessRx Novaliq Jiangsu Simcere Pharmaceutical Aadi Bioscience Eyestem Research
Sound Pharmaceuticals Intuitive Surgical Axsome Therapeutics Huons Biopharma Neuren Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.